From Tech to Deep Tech

people worldwide. In 2016, Roche invested
CHF 9.9 billion in R& D and posted sales
of CHF 50.6 billion. Genentech, in the
United States, is a wholly owned member
of the Roche Group. Roche is the majority
shareholder in Chugai Pharmaceutical,
Japan. For more information, please visit
www.roche.com.
• Access to an international network of
leading technology experts in Safran’s
business sectors.
• The global commercial and industrial
reach of Safran companies.
• Commercial and development
agreements to be implemented between
such startups and Safran’s own entities.
Safran,
Industry Partner
-
Safran is a leading international
high-technology group with three core
businesses: Aerospace (propulsion and
equipment), Defence and Security. Operating
worldwide, the Group has 70,000 employees
and generated sales of 17.4 billion euros
in 2015. Working independently or in
partnership, Safran holds world or European
leadership positions in its core markets.
The Group invests heavily in Research
& Development to meet the requirements
of changing markets, including expenditures
of more than 2 billion euros in 2015. Safran
is listed on Euronext Paris and is part of the
CAC40 index, as well as the Euro Stoxx 50
European index.
Established in 2015, Safran Corporate
Ventures is the Group’s corporate venture
capital arm. It funds startups that have
developed breakthrough or disruptive
technologies or business models which
will help Safran to address the challenges
of the aerospace, defense or security markets.
This new entity clearly reflects Safran’s
corporate strategy based on innovation
and transformation.
Safran Corporate Ventures will help agile,
innovation-driven companies by funding
their growth. These companies will also
benefit from:
Sycomore,
Industry Partner
-
Innovation. But what for? In our
connected world - undergoing
profound changes, shaken up
by digitalisation, challenged by
the environmental and energy
transition, and with ever widening
social inequalities - innovation is
a matter of survival. We all agree.
But what is the purpose of this
innovation?
The intensity and diversity that
characterise the spirit of the Hello
Tomorrow initiative naturally
lead to a key question: what are
these innovations all about? Not
all innovation is good. We can
no longer assume that “what I
undertake or what I do with my
money has little bearing, since I
help to keep the economy going”
in a Schumpeterian cycle of
endless creative destruction. We
now know that GDP growth is
a poor indicator for measuring
improvement in welfare, but is
46